WO2000078299A3 - Composition et procede pour prevenir les effets secondaires de chimiotherapie et/ou de radiotherapie ou pour en reduire la gravite - Google Patents

Composition et procede pour prevenir les effets secondaires de chimiotherapie et/ou de radiotherapie ou pour en reduire la gravite Download PDF

Info

Publication number
WO2000078299A3
WO2000078299A3 PCT/US2000/005186 US0005186W WO0078299A3 WO 2000078299 A3 WO2000078299 A3 WO 2000078299A3 US 0005186 W US0005186 W US 0005186W WO 0078299 A3 WO0078299 A3 WO 0078299A3
Authority
WO
WIPO (PCT)
Prior art keywords
severity
preventing
reducing
composition
side effects
Prior art date
Application number
PCT/US2000/005186
Other languages
English (en)
Other versions
WO2000078299A2 (fr
Inventor
Stephen Thomas Davis
Original Assignee
Glaxo Group Ltd
Stephen Thomas Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Stephen Thomas Davis filed Critical Glaxo Group Ltd
Priority to EP00970426A priority Critical patent/EP1177016A2/fr
Priority to AU79811/00A priority patent/AU7981100A/en
Priority to JP2001504363A priority patent/JP2003502362A/ja
Priority to US09/914,392 priority patent/US6620818B1/en
Publication of WO2000078299A2 publication Critical patent/WO2000078299A2/fr
Publication of WO2000078299A3 publication Critical patent/WO2000078299A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne une composition et un procédé pour prévenir les effets secondaires de cytotoxicité épithéliale (tels que l'alopécie, le syndrome plantaire-palmaire et/ou la mucosite) ou pour en réduire la gravité, lesdits effets secondaires apparaissant chez un sujet soumis à une chimiothérapie et/ou une radiothérapie; selon ce procédé, on administre simultanément au patient une quantité efficace d'un inhibiteur de kinase II dépendant de la cycline.
PCT/US2000/005186 1999-03-04 2000-03-01 Composition et procede pour prevenir les effets secondaires de chimiotherapie et/ou de radiotherapie ou pour en reduire la gravite WO2000078299A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00970426A EP1177016A2 (fr) 1999-03-04 2000-03-01 Composition et procede pour prevenir les effets secondaires de chimiotherapie et/ou de radiotherapie ou pour en reduire la gravite
AU79811/00A AU7981100A (en) 1999-03-04 2000-03-01 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2001504363A JP2003502362A (ja) 1999-03-04 2000-03-01 化学療法および／または放射線療法の副作用の苛酷さを防止／軽減するための組成物および方法
US09/914,392 US6620818B1 (en) 2000-03-01 2000-03-01 Method for reducing the severity of side effects of chemotherapy and/or radiation therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9904932.2A GB9904932D0 (en) 1999-03-04 1999-03-04 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904932.2 1999-03-04

Publications (2)

Publication Number Publication Date
WO2000078299A2 WO2000078299A2 (fr) 2000-12-28
WO2000078299A3 true WO2000078299A3 (fr) 2001-10-18

Family

ID=10848914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005186 WO2000078299A2 (fr) 1999-03-04 2000-03-01 Composition et procede pour prevenir les effets secondaires de chimiotherapie et/ou de radiotherapie ou pour en reduire la gravite

Country Status (5)

Country Link
EP (1) EP1177016A2 (fr)
JP (1) JP2003502362A (fr)
AU (1) AU7981100A (fr)
GB (1) GB9904932D0 (fr)
WO (1) WO2000078299A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CA2399274A1 (fr) 2000-02-07 2001-08-09 Mark E. Salvati Inhibiteurs 3-aminopyrazole des kinases dependantes des cyclines
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
PT1940839E (pt) 2005-10-07 2013-10-10 Exelixis Inc Inibidores de piridopirimidinona pi3k alfa
MX2009002927A (es) 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
KR101432171B1 (ko) 2013-01-22 2014-08-22 한국원자력의학원 Ｃｄｋ11ａ를 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012506A1 (fr) * 1994-10-24 1996-05-02 Baylor College Of Medecine Inhibiteurs de synthese d'adn produits dans des cellules senescentes
WO1997027297A1 (fr) * 1996-01-23 1997-07-31 Mitotix, Inc. Inhibiteurs de la progression du cycle cellulaire et leurs utilisations
WO1998050356A1 (fr) * 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1999010325A1 (fr) * 1997-08-06 1999-03-04 Glaxo Group Limited Derives de benzylidene-1,3-dihydro-indol-2-one utilises comme inhibiteurs des tyrosine-recepteur-kinases, notamment des raf-kinases
WO1999015500A1 (fr) * 1997-09-05 1999-04-01 Glaxo Group Limited Derives substitues d'oxindole en tant qu'inhibiteurs de la tyrosine kinase et de la serine/threonine kinase
WO1999052869A1 (fr) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Indolinones substituees a effet inhibiteur sur des kinases et des complexes cycline/cdk

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012506A1 (fr) * 1994-10-24 1996-05-02 Baylor College Of Medecine Inhibiteurs de synthese d'adn produits dans des cellules senescentes
WO1997027297A1 (fr) * 1996-01-23 1997-07-31 Mitotix, Inc. Inhibiteurs de la progression du cycle cellulaire et leurs utilisations
WO1998050356A1 (fr) * 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
WO1999010325A1 (fr) * 1997-08-06 1999-03-04 Glaxo Group Limited Derives de benzylidene-1,3-dihydro-indol-2-one utilises comme inhibiteurs des tyrosine-recepteur-kinases, notamment des raf-kinases
WO1999015500A1 (fr) * 1997-09-05 1999-04-01 Glaxo Group Limited Derives substitues d'oxindole en tant qu'inhibiteurs de la tyrosine kinase et de la serine/threonine kinase
WO1999052869A1 (fr) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Kg Indolinones substituees a effet inhibiteur sur des kinases et des complexes cycline/cdk

Also Published As

Publication number Publication date
EP1177016A2 (fr) 2002-02-06
JP2003502362A (ja) 2003-01-21
AU7981100A (en) 2001-01-09
WO2000078299A2 (fr) 2000-12-28
GB9904932D0 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
WO2000056296A3 (fr) Compositions favorisant la fecondite
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2003053336A3 (fr) Procedes de traitement de malaises neurovasculaires peripheriques
WO2001027109A3 (fr) Derives de tert.-butyl-(methyl-imidazo[1,2-a]pyridine-3-yl)amine
AU5835098A (en) Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
AU1211302A (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
NZ241210A (en) 16alpha,17alpha-butylidenedioxy-11b, 21-dihydroxypregn-4-ene-3,20-dione derivatives substituted in either or both the 6alpha- and 9alpha- positions by fluorine; pharmaceutical compositions, methods of preparation and treatment
WO2001062235A3 (fr) Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
WO2000078299A3 (fr) Composition et procede pour prevenir les effets secondaires de chimiotherapie et/ou de radiotherapie ou pour en reduire la gravite
HUP0301506A3 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
GB9521608D0 (en) Pharmaceutical composition
WO2001057042A3 (fr) Derives de pyrrole 4-pyridyl- et 2,4-pyrimidinyl-substitues et leur utilisation en pharmacie
HK1028190A1 (en) Compositions and articles for reducing the effectsof inflammation.
WO2000052013A3 (fr) Composes thiazolo-indolinoniques
WO2001085188A3 (fr) Utilisation d'echinacea comme agent hematinique
WO2002062334A3 (fr) Composes de chimioprevention des cancers et compositions et procedes de traitement des cancers
EP0161816A3 (fr) Urogastrone
EP0443028A4 (fr) Agent carcinostatique non injecte permettant de supprimer l'inflammation due a 5-fluorouracil, et procede de traitement du cancer.
WO2000040225A3 (fr) Inhibition de l'activite du tnf
AU2002212489A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
AU7941294A (en) Composition for the treatment or prevention of herpes
MY133682A (en) Substituted pyrroles
EP1161948A3 (fr) Composition pharmaceutique et nutritive pour traiter l'oedème cérébral
NO20010979D0 (no) FremgangsmÕte for Õ lindre de skadelige virkningene av interleukin-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09914392

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000970426

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 504363

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000970426

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2000970426

Country of ref document: EP